$498 Million is the total value of SABBY MANAGEMENT, LLC's 103 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CNBX | Exit | CANNABICS | $0 | – | -7,286 | -100.0% | 0.00% | – |
| Exit | INTEC PHARMA LTDcall | $0 | – | -175 | -100.0% | -0.00% | – | |
| SINT | Exit | SINTX TECHNOLOGIES INC | $0 | – | -18,272 | -100.0% | -0.00% | – |
| RBZHF | Exit | REEBONZ HOLDING LTD | $0 | – | -25,000 | -100.0% | -0.00% | – |
| Exit | TENAX THERAPEUTICS INC | $0 | – | -32,842 | -100.0% | -0.01% | – | |
| SYN | Exit | SYNTHETIC BIOLOGICS INC | $0 | – | -76,896 | -100.0% | -0.01% | – |
| Exit | ACELRX PHARMS INCput | $0 | – | -220 | -100.0% | -0.01% | – | |
| ADMP | Exit | ADAMIS PHARMACEUTICALS | $0 | – | -88,210 | -100.0% | -0.01% | – |
| SHIPZ | Exit | SEANERGY MARITIME*w | $0 | – | -897,499 | -100.0% | -0.02% | – |
| XBIO | Exit | XENETIC BIOSCIENCES INC | $0 | – | -60,523 | -100.0% | -0.02% | – |
| Exit | INVIVO THERAPEUTICS | $0 | – | -32,660 | -100.0% | -0.02% | – | |
| BLIN | Exit | BRIDGELINE DIGITAL INC | $0 | – | -110,000 | -100.0% | -0.03% | – |
| EARS | Exit | AURIS MEDICAL HOLDING | $0 | – | -89,451 | -100.0% | -0.03% | – |
| Exit | AMARIN CORP PLCcall | $0 | – | -188 | -100.0% | -0.03% | – | |
| BNTC | Exit | BENITEC BIOPHARMA LTDads | $0 | – | -21,592 | -100.0% | -0.04% | – |
| EFOI | Exit | ENERGY FOCUS INC | $0 | – | -267,298 | -100.0% | -0.04% | – |
| Exit | BELLICUM PHARMACEUTICALS | $0 | – | -18,927 | -100.0% | -0.04% | – | |
| NURO | Exit | NEUROMETRIX INC | $0 | – | -82,250 | -100.0% | -0.04% | – |
| Exit | GENPREX INCput | $0 | – | -441 | -100.0% | -0.04% | – | |
| Exit | APPLIED DNA SCIENCES INC | $0 | – | -26,397 | -100.0% | -0.04% | – | |
| ZSAN | Exit | ZOSANO PHARMA CORP | $0 | – | -203,536 | -100.0% | -0.05% | – |
| Exit | AKERS BIOSCIENCES INC | $0 | – | -55,400 | -100.0% | -0.05% | – | |
| Exit | OBALON THERAPEUTICS INC | $0 | – | -172,389 | -100.0% | -0.05% | – | |
| HEPA | Exit | HEPION PHARMACEUTICALS | $0 | – | -72,575 | -100.0% | -0.05% | – |
| MYO | Exit | MYOMO INC | $0 | – | -51,588 | -100.0% | -0.08% | – |
| Exit | NABRIVA THERAPEUTICS PLC | $0 | – | -367,613 | -100.0% | -0.09% | – | |
| HSDT | Exit | HELIUS MEDICAL | $0 | – | -746,316 | -100.0% | -0.10% | – |
| SEEL | Exit | SEELOS THERAPEUTICS INC | $0 | – | -508,000 | -100.0% | -0.10% | – |
| ASTC | Exit | ASTROTECH CORP NEW | $0 | – | -99,667 | -100.0% | -0.11% | – |
| COCP | Exit | COCRYSTAL PHARMA INC | $0 | – | -392,206 | -100.0% | -0.12% | – |
| PTE | Exit | POLARITYTE INC | $0 | – | -349,358 | -100.0% | -0.16% | – |
| PHIO | Exit | PHIO PHARMACEUTICALS | $0 | – | -255,194 | -100.0% | -0.19% | – |
| SRNE | Exit | SORRENTO THERAPEUTICS | $0 | – | -287,386 | -100.0% | -0.22% | – |
| AMRN | Exit | AMARIN CORP PLCadr | $0 | – | -150,000 | -100.0% | -0.25% | – |
| Exit | TRANSENTERIX INC | $0 | – | -1,760,262 | -100.0% | -0.26% | – | |
| IWM | Exit | ISHARES RUSSELL 2000etf | $0 | – | -5,900 | -100.0% | -0.28% | – |
| CTXR | Exit | CITIUS PHARMACEUTICALS | $0 | – | -1,354,275 | -100.0% | -0.34% | – |
| TTPH | Exit | TETRAPHASE | $0 | – | -667,000 | -100.0% | -0.36% | – |
| BXRX | Exit | BAUDAX BIO INC | $0 | – | -373,977 | -100.0% | -0.38% | – |
| Exit | BARCLAYS IPATHcall | $0 | – | -250 | -100.0% | -0.48% | – | |
| Exit | TRILLIUM THERAPEUTICS | $0 | – | -287,906 | -100.0% | -0.48% | – | |
| OTLK | Exit | OUTLOOK THERAPEUTICS INC | $0 | – | -3,232,342 | -100.0% | -0.81% | – |
| NOVN | Exit | NOVAN INC | $0 | – | -4,438,159 | -100.0% | -0.88% | – |
| GLD | Exit | SPDR GOLD TRUST | $0 | – | -17,934 | -100.0% | -1.10% | – |
| Exit | GILEAD SCIENCES INCcall | $0 | – | -2,166 | -100.0% | -1.15% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPDR S&P 500 ETF TRUST UNIT | 37 | Q3 2023 | 49.1% |
| ISHARES TR | 35 | Q3 2023 | 52.2% |
| SPDR S&P BIOTECHNOLOGY | 32 | Q3 2022 | 12.8% |
| AMARIN CORP PLC | 30 | Q4 2021 | 2.0% |
| BIOGEN INC | 24 | Q1 2021 | 26.2% |
| SAREPTA THERAPEUTICS INC | 24 | Q3 2020 | 4.6% |
| BIOGEN INC | 23 | Q1 2021 | 13.7% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2020 | 6.2% |
| BRAINSTORM CELL THERAPEUTICS INC | 21 | Q3 2023 | 1.6% |
| VERTEX PHARMACEUTICALS INC | 20 | Q1 2018 | 12.6% |
View SABBY MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AGM GROUP HOLDINGS, INC. | January 10, 2023 | 627,936 | 2.6% |
| Bit Digital, Inc | January 10, 2023 | 3,166,917 | 3.8% |
| Cingulate Inc. | January 10, 2023 | 10 | 5.0% |
| Context Therapeutics Inc. | January 10, 2023 | 796,706 | 5.0% |
| HeartBeam, Inc. | January 10, 2023 | 271,788 | 3.4% |
| PharmaCyte Biotech, Inc. | January 10, 2023 | 934,456 | 5.0% |
| Rebus Holdings, Inc.Sold out | January 10, 2023 | 0 | 0.0% |
| TANTECH HOLDINGS LTD | January 10, 2023 | 41,500 | 0.6% |
| Quanergy Systems, Inc. | January 04, 2023 | 936,905 | 5.8% |
| TuanChe Ltd | January 04, 2023 | 2,384,713 | 10.0% |
View SABBY MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-03 |
| SC 13G | 2024-01-03 |
| SC 13G | 2024-01-03 |
View SABBY MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.